Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A0B65S3
Wed, 09.12.2020
Paion AG
First Berlin Equity Research hat ein Research Update zu PAION AG (ISIN:
DE000A0B65S3) veröffentlicht. Analyst Simon Scholes bestätigt seine
BUY-Empfehlung und bestätigt sein Kursziel von EUR 4,90.
Zusammenfassung:
PAION hat positive Topline-Daten aus ihrer europäischen Phase-III-Studie
mit Remimazolam in der Indikation Allgem [ … ]
Tue, 01.12.2020
PAION AG
DR. JUERGEN BECK WILL LEAVE THE PAION AG MANAGEMENT BOARD ON 31 DECEMBER 2020 AS PLANNED
Aachen (Germany), 01 December 2020 - The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces that Dr. Juergen Beck will leave the Management Board of the company as planned at the end of his term o [ … ]
Thu, 19.11.2020
PAION AG
PAION REPORTS POSITIVE REMIMAZOLAM TOPLINE DATA IN EU PHASE III TRIAL IN GENERAL ANESTHESIA
- Primary endpoint met: remimazolam demonstrated non-inferiority to propofol for anesthetic effect
- Key secondary endpoint met: remimazolam demonstrated superior hemodynamic stability compared to propofol
- EU Phase III program completed; data to serve a [ … ]
Thu, 19.11.2020
PAION AG
PAION REPORTS POSITIVE REMIMAZOLAM TOPLINE DATA IN EU PHASE III TRIAL IN GENERAL ANESTHESIA
- Primary endpoint met: remimazolam demonstrated non-inferiority to propofol for anesthetic effect
- Key secondary endpoint met: remimazolam demonstrated superior hemodynamic stability compared to propofol
- EU Phase III program completed; data to serve as [ … ]
Wed, 11.11.2020
PAION AG
PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2020
- Significant progress with remimazolam with marketing approvals in the major markets U.S., Japan and China and launches in Japan and China
- BYFAVOTM designated as a Schedule IV medicine by DEA and now expected to be commercially available in the U.S. towards the e [ … ]
Tue, 06.10.2020
PAION AG
PAION REPORTS PROGRESS WITH BYFAVO(TM) (REMIMAZOLAM) BY ITS LICENSEE ACACIA IN THE U.S.
- Licensee Acacia clears final hurdle on path to commercial launch in the U.S.
- BYFAVOTM designated as a Schedule IV medicine by Drug Enforcement Administration
- BYFAVOTM expected to be commercially available in the U.S. before the end of 2020
Aachen (Germ [ … ]
Mon, 17.08.2020
PAION AG
First Berlin Equity Research hat ein Research Update zu PAION AG (ISIN:
DE000A0B65S3) veröffentlicht. Analyst Simon Scholes bestätigt seine
BUY-Empfehlung und bestätigt sein Kursziel von EUR 4,90.
Zusammenfassung:
Die Ergebnisse des ersten Halbjahres lagen nahe an unseren Erwartungen. Der
Umsatz betrug €3,5 Mio. (FBe: €3 [ … ]
Wed, 12.08.2020
PAION AG
PAION AG REPORTS FINANCIAL RESULTS FOR THE FIRST HALF-YEAR 2020
- Significant progress with remimazolam with marketing approvals in the important markets U.S., Japan and China
- Successful launch of Anerem(R) (remimazolam) by licensee Mundipharma in Japan
- Patient recruitment completed in EU Phase III trial
- Remimazolam license for Southeast [ … ]
Tue, 11.08.2020
PAION AG
PAION ANNOUNCES PROGRESS WITH REMIMAZOLAM BY ITS PARTNER YICHANG HUMANWELL IN CHINA
- Recent launch of Ruima(R) (remimazolam) in procedural sedation
- Yichang Humanwell has started a Phase III trial in general anesthesia
Aachen (Germany), 11 August 2020 - The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Sta [ … ]
Fri, 07.08.2020
PAION AG
PAION ANNOUNCES SUCCESSFUL PRODUCT LAUNCH OF ANEREM(R) (REMIMAZOLAM) IN JAPAN BY MUNDIPHARMA
Aachen (Germany), 07 August 2020 - The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces that Mundipharma, remimazolam licensee for Japan, informed PAION about the successful launch with firs [ … ]